Zymergen is a biofacturing company using biology to reimagine the world. Zymergen partners with nature to create, develop and manufacture breakthrough products and materials across a broad range of industries.
Company profile
Ticker
ZY
Exchange
Website
CEO
Joshua Hoffman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • OmniAb • SomaLogic ...
Former names
Zymergen, Inc.
SEC CIK
Corporate docs
Subsidiaries
1776 Pharmaceuticals LLC • enEvolv, Inc. • Genesis Acquisition Sub, LLC • Lodo Therapeutics Corporation • Zymergen International HoldCo Inc. • Zymergen Spain, S.L. • Zymergen Taiwan Co., Ltd. ...
IRS number
462942439
ZY stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
31 Oct 22
EFFECT
Notice of effectiveness
26 Oct 22
POS AM
Prospectus update (post-effective amendment)
19 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Oct 22
8-K
Ginkgo Bioworks Completes Acquisition of Zymergen
19 Oct 22
25-NSE
Exchange delisting
19 Oct 22
8-K
Submission of Matters to a Vote of Security Holders
17 Oct 22
425
Business combination disclosure
17 Oct 22
425
Business combination disclosure
12 Oct 22
Latest ownership filings
SC 13G/A
SB INVESTMENT ADVISERS (UK) LTD
21 Oct 22
4
Change in insider ownership
21 Oct 22
4
JAY T FLATLEY
19 Oct 22
4
Steven Chu
19 Oct 22
4
SANDRA E PETERSON
19 Oct 22
4
Travis Murdoch
19 Oct 22
4
Christine Marie Gorjanc
19 Oct 22
4
Rohit Sharma
19 Oct 22
4
Matthew Ocko
19 Oct 22
4
Enakshi Singh
19 Oct 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 226.57 mm | 226.57 mm | 226.57 mm | 226.57 mm | 226.57 mm | 226.57 mm |
Cash burn (monthly) | 40.65 mm | 30.16 mm | 38.82 mm | 30.41 mm | 18.28 mm | 19.58 mm |
Cash used (since last report) | 851.84 mm | 632.13 mm | 813.51 mm | 637.27 mm | 383.03 mm | 410.29 mm |
Cash remaining | -625.27 mm | -405.56 mm | -586.94 mm | -410.70 mm | -156.46 mm | -183.72 mm |
Runway (months of cash) | -15.4 | -13.4 | -15.1 | -13.5 | -8.6 | -9.4 |
Institutional ownership, Q1 2023
12.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 54.21 mm |
Total shares | 13.02 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
GIC Private | 5.08 mm | $33.98 mm |
Data Collective II | 4.92 mm | $0.00 |
True Ventures IV | 3.02 mm | $20.24 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Oct 22 | Travis Murdoch | Common Stock | Sale back to company | Dispose D | No | No | 0 | 79,697 | 0.00 | 0 |
19 Oct 22 | Enakshi Singh | Common Stock | Sale back to company | Dispose D | No | No | 0 | 462,241 | 0.00 | 0 |
19 Oct 22 | Enakshi Singh | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 10.14 | 49,233 | 499.22 k | 0 |
19 Oct 22 | Enakshi Singh | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 26.88 | 173,913 | 4.67 mm | 0 |
19 Oct 22 | Enakshi Singh | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 10 | 154,000 | 1.54 mm | 0 |
19 Oct 22 | Enakshi Singh | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 4.47 | 81,132 | 362.66 k | 0 |
19 Oct 22 | Peterson Sandra E | Common Stock | Sale back to company | Dispose D | No | No | 0 | 119,119 | 0.00 | 0 |
19 Oct 22 | Peterson Sandra E | Stock Options Common Stock | Sale back to company | Dispose D | No | No | 9.6 | 133,333 | 1.28 mm | 0 |
19 Oct 22 | Zachariah Serber | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 40,000 | 0.00 | 0 |
19 Oct 22 | Zachariah Serber | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 40,000 | 0.00 | 0 |